COMPANY PROFILE

MDxHealth

Explore full profile

Prostate Cancer Diagnostics and Confirmation Tests - MDxHealth

Liège, BelgiumFounded 2003Biotech & Life Sciences

Valuation $207M Market cap · 2025

Revenue $97M Latest reported FY

Total funding $0–10M Disclosed equity funding

About MDxHealth

Mdxhealth is a commercial stage precision diagnostics company specializing in providing actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The company operates in the healthcare sector, specifically focusing on urologic oncology. Mdxhealth serves healthcare providers, including urologists and oncologists, by offering advanced diagnostic tests that utilize proprietary genetic, epigenetic methylation, and other molecular technologies. These tests assist physicians in making informed decisions regarding the diagnosis and prognosis of prostate cancer, helping to determine the most appropriate course of treatment for patients.

Read full description

Mdxhealth's business model revolves around the development, validation, and commercialization of its diagnostic tests. The company generates revenue through the sale of these tests to healthcare providers and institutions. By offering precise and personalized diagnostic solutions, Mdxhealth aims to improve patient outcomes and optimize treatment strategies, thereby addressing a critical need in the market for more accurate and individualized cancer diagnostics.

Source: Dealroom company data